1. Home
  2. RYOJ vs ELTX Comparison

RYOJ vs ELTX Comparison

Compare RYOJ & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo rYojbaba Co. Ltd.

RYOJ

rYojbaba Co. Ltd.

N/A

Current Price

$2.74

Market Cap

56.9M

ML Signal

N/A

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

N/A

Current Price

$1.79

Market Cap

63.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RYOJ
ELTX
Founded
2015
2011
Country
Japan
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.9M
63.3M
IPO Year
2024
2014

Fundamental Metrics

Financial Performance
Metric
RYOJ
ELTX
Price
$2.74
$1.79
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $13.67
AVG Volume (30 Days)
11.0K
★ 304.4K
Earning Date
03-23-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.29
EPS
★ N/A
N/A
Revenue
N/A
★ $2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.04
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.56
$1.71
52 Week High
$11.43
$16.00

Technical Indicators

Market Signals
Indicator
RYOJ
ELTX
Relative Strength Index (RSI) 33.25 27.54
Support Level $2.84 $1.74
Resistance Level $2.95 $3.32
Average True Range (ATR) 0.31 0.11
MACD -0.06 0.04
Stochastic Oscillator 15.72 21.43

Price Performance

Historical Comparison
RYOJ
ELTX

About RYOJ rYojbaba Co. Ltd.

rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: